🔎 Trials Near Me

Domov › Debelost › Tennessee

Klinične študije za Debelost v Tennessee

38 študij za Debelost išče udeležence na lokacijah v Tennessee.

Mesta v Tennessee

Uradno besedilo študije (angleško)

Safety and Efficacy of ABBV-295 in Adults With Obesity or Overweight With Weight-Related Comorbidities

  • Holston Medical Group - Bristol /ID# 282045, Bristol
  • New Phase Research & Development /ID# 282131, Knoxville
  • Summit Medical Group- Halls Family Physicians /ID# 282435, Knoxville
  • in še 1
Vključevanje udeležencevFaza 2
Starost 18–75 · Vsi spoli · Posodobljeno 2. okt. 2026 · NCT07752979

AMAZE 2: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Type 2 Diabetes Lose Weight

  • M3 Wake Research Chattanooga, Chattanooga
Vključevanje udeležencevFaza 3
Starost 18 in več · Vsi spoli · Posodobljeno 30. sep. 2026 · NCT07533175

A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight

  • LifeDoc Health, Memphis
Vključevanje udeležencevFaza 3
Starost 8–18 · Vsi spoli · Posodobljeno 30. sep. 2026 · NCT07253285

Study to Assess the Effect and Safety of ALV-100 on Maintenance of Weight Loss

  • AMR Clinical, Nashville
Vključevanje udeležencevFaza 2
Starost 18–75 · Vsi spoli · Posodobljeno 28. sep. 2026 · NCT07837973

Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight

  • Gastroenterology Center Of The Midsouth, Cordova
Vključevanje udeležencevFaza 3
Starost 18–70 · Vsi spoli · Posodobljeno 24. sep. 2026 · NCT06937099

A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)

  • Vanderbilt Health One Hundred Oaks, Nashville
Vključevanje udeležencevFaza 3
Starost 6–17 · Vsi spoli · Posodobljeno 24. sep. 2026 · NCT06672549

Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study

  • Gastroenterology Center Of The Midsouth, Cordova
Vključevanje udeležencevFaza 3
Starost 18–70 · Vsi spoli · Posodobljeno 24. sep. 2026 · NCT06937086

A Study to Evaluate Effect of AZD6234 in Adult Participants With Type 2 Diabetes Mellitus and Obesity or Overweight

  • Research Site, Franklin
  • Research Site, Jackson
  • Research Site, Knoxville
Vključevanje udeležencevFaza 3
Starost 18 in več · Vsi spoli · Posodobljeno 22. sep. 2026 · NCT07784270

Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity

  • Stern Cardiovascular Foundation Inc, Germantown
  • Accellacare of Knoxville, Knoxville
  • Cardiovascular Research of Knoxville North Knoxville Medical Center, Powell
  • in še 1
Vključevanje udeležencevFaza 3
Starost 45–99 · Vsi spoli · Posodobljeno 22. sep. 2026 · NCT07037433

A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes

  • AMR Clinical, Nashville
Vključevanje udeležencevFaza 3
Starost 18 in več · Vsi spoli · Posodobljeno 22. sep. 2026 · NCT07321886

A Study to Investigate Weight Management With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or Overweight

  • Quality Medical Research, Nashville
Vključevanje udeležencevFaza 2
Starost 18–75 · Vsi spoli · Posodobljeno 22. sep. 2026 · NCT07589608

Transition to Ambulatory Bariatric Surgery (TABS) Trial

  • Vanderbilt University Medical Center, Nashville
Vključevanje udeležencev
Starost 25–55 · Vsi spoli · Posodobljeno 21. sep. 2026 · NCT07011628

A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities

  • AURORA-1 Clinical Site, Memphis
Vključevanje udeležencevFaza 3
Starost 18 in več · Vsi spoli · Posodobljeno 16. sep. 2026 · NCT07743463

A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Type 2 Diabetes

  • AURORA-2 Clinical Site, Memphis
Vključevanje udeležencevFaza 3
Starost 18 in več · Vsi spoli · Posodobljeno 16. sep. 2026 · NCT07743450

Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity

  • Apex Research Foundation, LLC, Jackson
  • The Jackson Clinic PA, Jackson
  • Parkway Cardiology Associates, Oak Ridge
  • in še 2
Vključevanje udeležencevFaza 3
Starost 18–99 · Vsi spoli · Posodobljeno 16. sep. 2026 · NCT07037459

A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight Without Type 2 Diabetes

  • Innovative Clinical Research, Clarksville
  • Clinical Research Associates, Nashville
Vključevanje udeležencevFaza 3
Starost 18 in več · Vsi spoli · Posodobljeno 14. sep. 2026 · NCT07351045

A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)

  • ACCOMPLISH-2 Research Site, Nashville
Vključevanje udeležencevFaza 3Vabljeni zdravi prostovoljci
Starost 18–79 · Vsi spoli · Posodobljeno 11. sep. 2026 · NCT07654374

A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight

  • Quality Medical Research, Nashville
Vključevanje udeležencevFaza 2
Starost 18–75 · Vsi spoli · Posodobljeno 8. sep. 2026 · NCT06143956

Efficacy and Safety of Ribupatide Administered Once Weekly in Participants Living With Obesity or Overweight and Diabetes

  • Kailea Clinical Site, Memphis
Vključevanje udeležencevFaza 3
Starost 18 in več · Vsi spoli · Posodobljeno 3. sep. 2026 · NCT07284901

Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-1-EXTENSION)

  • New Phase Research and Development, Knoxville
Vključevanje udeležencevFaza 3
Starost 18–99 · Vsi spoli · Posodobljeno 3. sep. 2026 · NCT07684235

Efficacy and Safety of Ribupatide in Participants Living With Obesity or Overweight With Weight-Related Comorbidities Who Do Not Have Diabetes

  • Kailera Clinical Site, Chattanooga
Vključevanje udeležencevFaza 3
Starost 18 in več · Vsi spoli · Posodobljeno 3. sep. 2026 · NCT07284875

The Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial Function

  • Vanderbilt University Medical Center, Nashville
Vključevanje udeležencevFaza 1/2
Starost 18 in več · Vsi spoli · Posodobljeno 1. sep. 2026 · NCT05972564

A Study to Evaluate Effect of AZD6234 in Adult Participants With Obesity or Overweight With Weight-related Comorbidity Without Type 2 Diabetes Mellitus

  • Research Site, Kingsport
Vključevanje udeležencevFaza 3
Starost 18 in več · Vsi spoli · Posodobljeno 25. avg. 2026 · NCT07784725

A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity

  • Balad Hlth Sys-Welmont CardCVA, Greeneville
  • The Jackson Clinic, PA, Jackson
Vključevanje udeležencevFaza 3
Starost 18 in več · Vsi spoli · Posodobljeno 18. avg. 2026 · NCT07567001

Efficacy and Safety of Aleniglipron in Participants With Obesity or Overweight With a Weight-Related Comorbidity (ACCOMPLISH-1)

  • ACCOMPLISH-1 Research Site, Knoxville
Vključevanje udeležencevFaza 3
Starost 18–79 · Vsi spoli · Posodobljeno 10. avg. 2026 · NCT07654361

Atomoxetine in Melanocortin Obesity Syndrome

  • Vanderbilt University Medical Center, Nashville
Vključevanje udeležencevFaza 2
Starost 6 in več · Vsi spoli · Posodobljeno 7. avg. 2026 · NCT06899178

A Study to Improve Skeletal Muscle in Veterans With HIV

  • Tennessee Valley Healthcare System Nashville Campus, Nashville, TN, Nashville
Vključevanje udeležencev
Starost 20–80 · Moški · Posodobljeno 26. jun. 2026 · NCT06845046

Evaluation of the Tolerability of Cagrilintide in Participants Not Tolerating GLP-1-RA Therapies Due to Gastrointestinal Adverse Events

  • Holston Medical Group_Bristol, Bristol
Vključevanje udeležencevFaza 1
Starost 18 in več · Vsi spoli · Posodobljeno 25. jun. 2026 · NCT07607587

Daily Eating Patterns for Total Health Study

  • Healthy Eating and Activity Laboratory, Knoxville
Vključevanje udeležencev
Starost 25–60 · Vsi spoli · Posodobljeno 15. jun. 2026 · NCT06455995

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MBX 4291 in Adult Participants With Obesity

  • MBX Biosciences Investigational Site, Knoxville
Vključevanje udeležencevFaza 1
Starost 18–65 · Vsi spoli · Posodobljeno 9. jun. 2026 · NCT07142707

EBT Fruit and Vegetable Prescription

  • Cherokee Health Systems, Dameron Avenue Pedatrics, Knoxville
Vključevanje udeležencevVabljeni zdravi prostovoljci
Starost 4–10 · Vsi spoli · Posodobljeno 9. jun. 2026 · NCT05028205

Resistance Exercise and Incretin Mimetic for Cardiometabolic Health in Survivors of ALL With Obesity

  • St. Jude Children's Research Hospital, Memphis
Vključevanje udeležencevFaza 2
Starost 18 in več · Vsi spoli · Posodobljeno 4. jun. 2026 · NCT07228741

Metabolic Effects of Angiotensin-(1-7)

  • Vanderbilt University Medical Center, Nashville
Vključevanje udeležencevFaza 1
Starost 18–60 · Vsi spoli · Posodobljeno 22. maj 2026 · NCT02646475

Sympathetic Mechanisms in Obesity-Crossover Design

  • Vanderbilt University Medical Center, Nashville
Vključevanje udeležencevFaza 1/2
Starost 18–65 · Vsi spoli · Posodobljeno 27. feb. 2026 · NCT05312892

A Study of RM-718 in Healthy Subjects and Patients With MC4R Pathway Impairment

  • Vanderbilt University Medical Center (Part C only), Nashville
Vključevanje udeležencevFaza 1/2Vabljeni zdravi prostovoljci
Starost 12–65 · Vsi spoli · Posodobljeno 22. dec. 2025 · NCT06239116

Tirzepatide in PWS, HO and GNSO

  • Vanderbilt University Medical Center, Nashville
Vključevanje udeležencevFaza 4
Starost 18–26 · Vsi spoli · Posodobljeno 16. sep. 2025 · NCT06901245

Relationship Between Aspirin Metabolism and Markers of Metabolic Dysfunction Among Pregnant Persons at Risk of Pre-eclampsia

  • University of Tennessee Medical Center, Knoxville
Vključevanje udeležencevOpazovalna študija
Starost 18–45 · Ženske · Posodobljeno 10. sep. 2025 · NCT06802861

Vir: ClinicalTrials.gov, podatki pridobljeni 5. okt. 2026. Vsaka študija ima svoje pogoje vključitve; ekipa študije odloči, kdo lahko sodeluje.